Word for Pharming Group NV in mid-January of an action date regarding the supplemental BLA for the C1-esterase inhibitor Ruconest, followed by news four days later that Biocryst Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. will merge, added yet another shift in the hereditary angioedema (HAE) space. Read More
Drug pricing pressures, regulatory uncertainty and sizeable financings opportunities all may have contributed to an M&A slowdown in 2017 that left the biopharmaceutical industry with the lowest value of completed deals in four years and the lowest number of deals in three. Read More
